St. John's wort Hypericum perforatum L.
Also called: hypericum, Klamath weed, goatweed
St. John's wort is a yellow-flowered plant used in Greek, Islamic and Chinese traditional medicine. Extracts are prepared from the flowers and leaves. It interacts with many prescription medicines.
- Category
- Botanical
- Part used
- Flowers and leaves
- Strongest evidence
- A Strong
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2008 Cochrane review included 29 randomized double-blind trials (5,489 patients with major depression) comparing St John's wort extracts with placebo (18 comparisons) or standard antidepressants (17 comparisons). [3]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
ABrain, mood and sleep2 topics
CSeveral areas, whole body or blood1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Major depression | A | Cochrane (2008): 29 trials, 5,489 patients; extracts beat placebo, matched standard antidepressants, with fewer dropouts from side effects. Trials from German-speaking countries were more favorable, complicating interpretation. [3] |
| Severe depression or use beyond 12 weeks | C | NCCIH states it is uncertain whether benefit applies to severe depression or periods longer than 12 weeks. [1] |
| Menopausal hot flashes and somatic symptom disorder | C | Small numbers of studies suggest it may help. [1] |
| ADHD, IBS, OCD, PMS, smoking cessation, wound healing | C | Only a small amount of research for each; NCCIH states it has not clearly been shown helpful for any. [1] |
Main constituents: Hypericin, pseudohypericin and hyperforin are the most likely active candidates; the active principle is not known [2]
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated March 28, 2020).
Details and sources - Pregnancy and breastfeedingEU monograph: safety during pregnancy and breast-feeding has not been established; animal studies showed signs of reproductive toxicity …
2 statements in the profile.
Details and sources - Interactions with medicines6 listed
Drugs metabolized by CYP3A4, CYP2B6, CYP2C9, CYP2C19 or transported by P-glycoprotein; Hormonal contraceptives; Serotonin reuptake inhibitors (e.g.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographs2 statements
EU (HMPC monograph Revision 1, adopted 23 November 2022), well-established use for mild to moderate depressive episodes, adults and elderly: dry …
Details and sources
- NCCIH states it has been clearly shown that St. John's wort can interact in dangerous, sometimes life-threatening ways with a variety of medicines. [1]
- For adults not taking any medicine, appears safe for up to 12 weeks; some studies indicate safe use for a year or more. [1]
- Large oral doses or skin application might cause severe skin reactions after sun exposure. Other effects: diarrhea, dizziness, trouble sleeping, restlessness, skin tingling. [1]
- May be unsafe in pregnancy (possible birth-defect risk). Breastfed infants of mothers taking it can have colic, drowsiness and lethargy. [1]
- LiverTox likelihood score E (unlikely cause of clinically apparent liver injury); interactions may change the liver risk of other drugs. [2]
Interactions
| With | What happens |
|---|---|
| Many prescription drugs (CYP3A4, CYP2C9, P-glycoprotein) | Induces CYP3A4 and CYP2C9 and affects the drug transporter P-glycoprotein, which can weaken many medicines. [2] |
| Birth control pills | St. John's wort can weaken their effects. [1] |
| Cyclosporine | Can weaken its effect in preventing transplant rejection. [1] |
| Warfarin; digoxin; ivabradine; simvastatin | Can weaken the effects of these medicines. [1] |
| HIV drugs (indinavir, nevirapine) and cancer drugs (irinotecan, imatinib, docetaxel) | Can weaken the effects of these medicines. [1] |
| Antiseizure drugs (phenytoin, carbamazepine); antidepressants (amitriptyline, bupropion) | Can weaken their effects. With certain antidepressants or other serotonin-affecting drugs, serious serotonin-related side effects may occur. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
- EU: the HMPC adopted a final EU herbal monograph on Hypericum perforatum L., herba (Revision 1, first published February 22, 2023), covering well-established use and traditional use. [4]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Hypericin and pseudohypericin (leading candidates; LiverTox states the active principle is not known) Naphthodianthrones [P1]
- Hyperforin (phloroglucinol derivative); the EU monograph states that naphthodianthrones, phloroglucinol derivatives and flavonoids contribute to the activity, and that hyperforin induces CYP3A4, CYP2B6, CYP2C9, CYP2C19 and P-glycoprotein via the PXR system Phloroglucinols (acylphloroglucinol) [P2]
- Flavonoids (e.g. rutin, hyperoside, isoquercitrin, quercitrin) and phenolic acids (e.g. chlorogenic acid) Flavonoids and phenolic acids [P4]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming St. John's wort (Hypericum perforatum), as part of a three-botanical combination extract (NDI 1208 submitted 2021-06-01). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P6]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of St. John's wort was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P7]
Liver (NIH LiverTox)
- LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated March 28, 2020). [P1]
Interactions with medicines
- Drugs metabolized by CYP3A4, CYP2B6, CYP2C9, CYP2C19 or transported by P-glycoprotein: EU monograph: Hyperici herba preparations induce these enzymes and P-glycoprotein; concomitant use with coumarin-type anticoagulants, cyclosporine, everolimus, sirolimus, systemic tacrolimus, fosamprenavir, indinavir and other protease inhibitors, nucleoside reverse transcriptase inhibitors, irinotecan, imatinib and other cytostatic agents metabolized by these pathways is contraindicated. Elevated enzyme activity returns to normal within 1 week after stopping. [P2]
- Amitriptyline, fexofenadine, alprazolam, diazepam, midazolam, methadone, simvastatin, digoxin, finasteride: EU monograph: special care is needed because a reduction of plasma concentrations is possible. [P2]
- Hormonal contraceptives: EU monograph: reduced plasma concentrations may lead to increased intermenstrual bleeding and reduced safety in birth control; additional contraceptive measures are advised. [P2]
- Serotonin reuptake inhibitors (e.g. sertraline, paroxetine), buspirone: EU monograph: may contribute to serotonergic effects; very rarely serotonin syndrome can occur in combination with serotonergic substances. [P2]
- Anesthesia (elective surgery): EU monograph: possible interactions with products used in general and regional anesthesia should be identified before elective surgery; if necessary the product should be discontinued. [P2]
- Bupropion, phenytoin, carbamazepine, ivabradine, nevirapine, docetaxel, warfarin: NCCIH lists these among medicines whose effects St. John's wort can weaken. [P3]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- BAPP laboratory guidance (2021): many Hypericum species (H. androsaemum, H. barbatum, H. crux-andreae, H. hirsutum, H. humifusum, H. maculatum, H. montanum, H. patulum, H. tetrapterum) have been reported as adulterants; undeclared synthetic dyes (amaranth/FD&C Red #2, brilliant blue/FD&C Blue #1, sunset yellow/FD&C Yellow #6, tartrazine/FD&C Yellow #5) have been added to bolster absorbance readings when hypericin is measured by spectrophotometry. The program also published a Hypericum perforatum adulterants bulletin in 2017. [P4]
- BAPP review (2023): brilliant blue, and to a lesser extent amaranth, absorbs at 590 nm, the wavelength used to measure hypericin; dye adulteration can be detected using HPTLC or HPLC-UV/vis fingerprints. [P5]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of the dietary ingredient (at least one appropriate test or examination) — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petitioned under 111.75(a)(1)(ii). [P8]
- HPTLC or HPLC-UV/vis fingerprint (not UV spectrophotometry alone) — UV spectrometry cannot detect adulteration with dyes or other Hypericum species; HPTLC and HPLC can detect small amounts of adulterants and HPTLC can detect synthetic dyes. [P4]
- Genetic (DNA) identification for whole, cut or powdered herb — Able to distinguish closely related Hypericum species; cannot detect chemical adulterants such as dyes. [P4]
- Macroscopic check for black hypericin glands and opposing ridges on the stem — Absence of the characteristic black hypericin glands on stems, leaves and petals may give the first indication of adulteration; macroscopic assessment is difficult or impossible for finely cut and sifted material. [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- EU monograph: hypericin reaches maximum plasma concentration 4–12 hours after intake, with an elimination half-life of about 19–36 hours. [P2]
- EU monograph: hyperforin reaches maximum levels about 3–4 hours after administration, with an elimination half-life of about 15–63 hours; hyperforin can cross the blood-brain barrier. [P2]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (HMPC monograph Revision 1, adopted 23 November 2022), well-established use for mild to moderate depressive episodes, adults and elderly: dry extract (DER 3-7:1, methanol 80% V/V) 300–600 mg 1–3 times daily (600–1800 mg/day); dry extract (DER 3-6:1, ethanol 80% V/V) 900 mg once daily. Use under 18 years not recommended. [P2]
- EU (same monograph), traditional use for temporary mental exhaustion, adults and elderly: dry extract (DER 4-7:1, ethanol 38% m/m) 60–180 mg 2–3 times daily (180–360 mg/day). The monograph lists further traditional-use preparations, including cutaneous oily preparations. [P2]
Pregnancy and breastfeeding
- EU monograph: safety during pregnancy and breast-feeding has not been established; animal studies showed signs of reproductive toxicity; use is not recommended during pregnancy and lactation. [P2]
- NCCIH: may be unsafe in pregnancy because it may increase the risk of birth defects; breastfed infants of mothers taking it can have colic, drowsiness and lethargy. [P3]
Sources for this profile
- NIH LiverTox (NIDDK). St. John's Wort (Last Update: March 28, 2020), 2020-03-28. ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1 (EMA/HMPC/7695/2021, adopted 23 November 2022), 2022-11-23. ema.europa.eu
- NCCIH. St. John's Wort: Usefulness and Safety (Last Updated: May 2025), 2025-05. nccih.nih.gov
- Orhan N. St. John's wort (Hypericum perforatum) laboratory guidance document. ABC-AHP-NCNPR Botanical Adulterants Prevention Program; 2021 (doi 10.59520/bapp.lgd/AwBq3781), 2021. umb.herbalgram.org
- Gafner S, Blumenthal M, Foster S, Cardellina JH 2nd, Khan IA, Upton R. Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods for Authenticating Herbal Dietary and Food Ingredients and Supplements (review of ABC-AHP-NCNPR Botanical Adulterants Prevention Program publications). J Nat Prod. 2023;86(2):460-472, 2023-02-24. pmc.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (agents classified by the IARC Monographs; checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- NCCIH. St. John's Wort: Usefulness and Safety (Last Updated: 2025-05), 2025-05. nccih.nih.gov
- NIH LiverTox (NIDDK). St. John's Wort (Last Update: 2020-03-28), 2020-03-28. ncbi.nlm.nih.gov
- Cochrane Database of Systematic Reviews. Linde K, Berner MM, Kriston L. St John's wort for major depression. 2008;(4):CD000448 (PubMed abstract, PMID 18843608), 2008-10-08. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. Hyperici herba (St. John's wort) - herbal medicinal product, 2023-02-22. ema.europa.eu
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.